Puma Biotechnology Stock Market Value
| PBYI Stock | USD 6.16 0.01 0.16% |
| Symbol | Puma |
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Puma Biotechnology's market capitalization is 312.89 M. A P/B ratio of 2.34 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 236.28 M. Intrinsic value reflects what Puma Biotechnology's fundamentals imply about worth, which may differ from both price and book figure. Valuation work aligns these measures into a single analytical context. This dataset reflects observed data and is not advisory in nature.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.34, a profit margin of 13.62%, and ROE of 27.97%. By contrast, Puma Biotechnology market price reflects the level where buyers and sellers transact. This summary reflects available observations without forecasting intent.
What if' Analysis
Historical what-if analysis for Puma Biotechnology is useful because it converts abstract timing questions into a structured review of past performance under changing entry and holding periods. Current market capitalization is about 312.89 Million, enterprise value is near 236.28 Million, and annual revenue is around 228.37 Million. The point is not to predict the future from one chart, but to understand how sensitive the trade has been to timing and holding assumptions.
| 12/20/2025 |
| 03/20/2026 |
A 0.00 entry into Puma Biotechnology on December 20, 2025 held to the present would generate 0.00 in net gains. This amounts to a 0.0% net return in Puma Biotechnology on balance across a 90 day span. Trading data across multiple sessions provides the basis for all values shown. This overview is based on available data and does not express a directional view. Puma Biotechnology's competitive landscape includes Eledon Pharmaceuticals, Abeona Therapeutics, Voyager Therapeutics, Atea Pharmaceuticals, Arcturus Therapeutics, Allogene Therapeutics, and Humacyte. The list provides context for relative analysis. Competitors are identified based on business overlap and sector alignment. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to e... More
Puma Biotechnology Upside and Downside Indicators Summary
These indicators describe how Puma Biotechnology momentum evolves across recent price ranges. They provide a structured view of short-term momentum and range behavior.
| Downside Deviation | 5.31 | |||
| Information Ratio | 0.0577 | |||
| Maximum Drawdown | 30.34 | |||
| Value At Risk | -3.92 | |||
| Potential Upside | 4.39 |
Market Risk Indicators for Puma Biotechnology Snapshot
Return variability and drawdown behavior for Puma Biotechnology are summarized through these risk indicators. The measures describe how returns have dispersed relative to historical norms. Trading data across multiple sessions provides the basis for all values shown. This overview is based on available data and does not express a directional view.| Risk Adjusted Performance | 0.0401 | |||
| Jensen Alpha | 0.2873 | |||
| Total Risk Alpha | 0.6231 | |||
| Sortino Ratio | 0.0467 | |||
| Treynor Ratio | 0.1116 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Puma Biotechnology's price to converge to an average value over time is called mean reversion.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0401 | |||
| Market Risk Adjusted Performance | 0.1216 | |||
| Mean Deviation | 2.59 | |||
| Semi Deviation | 5.03 | |||
| Downside Deviation | 5.31 | |||
| Coefficient Of Variation | 2484.5 | |||
| Standard Deviation | 4.3 | |||
| Variance | 18.49 | |||
| Information Ratio | 0.0577 | |||
| Jensen Alpha | 0.2873 | |||
| Total Risk Alpha | 0.6231 | |||
| Sortino Ratio | 0.0467 | |||
| Treynor Ratio | 0.1116 | |||
| Maximum Drawdown | 30.34 | |||
| Value At Risk | -3.92 | |||
| Potential Upside | 4.39 | |||
| Downside Variance | 28.2 | |||
| Semi Variance | 25.3 | |||
| Expected Short fall | -2.62 | |||
| Skewness | -2.78 | |||
| Kurtosis | 18.19 |
Puma Biotechnology Backtested Returns
Puma Biotechnology appears to exhibit a moderate volatility over the selected 3 months investment horizon. It maintains a Sharpe Ratio of 0.0443, suggesting a return-to-volatility ratio of 0.0443. Indicator analysis identified thirty signals affecting performance dispersion. Please review metrics such as Coefficient Of Variation of 2484.5, risk-adjusted performance of 0.0401, and Semi Deviation of 5.03 to confirm whether our risk estimates align with your expectations. On a scale of 0 to 100, Puma Biotechnology holds a performance score of 3. The company has a beta of 1.46, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Puma Biotechnology will likely underperform. Please check Puma Biotechnology's expected short fall, and the relationship between the maximum drawdown and rate of daily change, to make a quick decision on whether Puma Biotechnology's existing price patterns will revert.
Auto-correlation | -0.49 |
Modest reverse predictability
Comparing Puma Biotechnology's price behavior from 20th of December 2025 to 3rd of February 2026 with the period from 3rd of February 2026 to 20th of March 2026 produces modest reverse predictability. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of Puma Biotechnology may be projected. The coefficient of -0.49 links about 49.0% of Puma Biotechnology's present price action to its own historical movements. Given that Puma Biotechnology has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.49 | |
| Spearman Rank Test | -0.71 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Currently Active Assets on Macroaxis
| DVLT | Datavault AI | |
| SEDG | SolarEdge Technologies | |
| CSIQ | Canadian Solar | |
| FLNC | Fluence Energy | |
| EDPFY | EDP Energias de |